Loading
Latest filing published 03 Apr 2026 for 셀트리온제약, €13.
No signal scores available.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
All filings by 김주범 on record concern 셀트리온제약, in the capacity of chief executive. The record holds 4 filings, for trades running from 26 March 2024 to 24 March 2026.
On the market, this insider has only ever bought: 4 purchases, €37 in total. The amount is not disclosed for 2 filings. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Since January 2026: 2 purchases and no sales on the market.
On 3 April 2026 came the latest disclosure, an open-market purchase for €13 in 셀트리온제약. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations